Galenea Corp. has entered a strategic collaboration with Eisai Co. Ltd., under which Galenea will apply its synaptic transmission platform technology to address synaptic dysfunction in neurodegenerative diseases. The collaboration aims discover and develop novel therapeutics for neurodegeneration mediated by a disease-specific protein. Eisai will make an undisclosed upfront payment and milestone payments throughout the program.   Galenea’s approach addresses disease mechanism using MANTRA, a hig...